Published in final edited form as:

J Thromb Thrombolysis. 2016 May ; 41(4): 569–580. doi:10.1007/s11239-016-1351-6.

Acute and Long-Term Effect of Percutaneous Coronary Intervention on Serially-Measured Oxidative, Inflammatory, and Coagulation Biomarkers in Patients with Stable Angina

Gregor Leibundgut^{§,*}, Jun-Hee Lee[&], Amit Segev^{‡,§§}, Bradley H. Strauss^{‡,f}, and Sotirios Tsimikas^{*}

[§]Division of Cardiology, University of Basel, Basel Switzerland [&]Division of Cardiology, Kang-Dong Sacred Heart Hospital, Hallym University Medical Center, Seoul, Korea [‡]Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada ^{§§}The Heart Centre, Chaim Sheba Medical Centre, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Israel ^fSchulich Heart Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Ontario, Canada ^{*}Department of Medicine, University of California San Diego, La Jolla, CA, USA

Abstract

Objectives—To derive insights into the temporal changes in oxidative, inflammatory and coagulation biomarkers in patients with stable angina undergoing percutaneous coronary intervention (PCI).

Background—PCI is associated with a variety of biochemical and mechanical stresses to the vessel wall. Oxidized phospholipids are present on plasminogen (OxPL-PLG) and potentiate fibrinolysis in vitro. We recently showed that OxPL-PLG increase following acute myocardial infarction, suggesting that they are involved in atherothrombosis.

Methods—Plasma samples were collected before, immediately after, 6 and 24 hours, 3 and 7 days, and 1, 3, and 6 months after PCI in 125 patients with stable angina undergoing uncomplicated PCI. Plasminogen levels, OxPL-PLG, and array of 16 oxidative, inflammatory and coagulation biomarkers were measured with established assays.

Results—OxPL-PLG and plasminogen declined significantly immediately post-PCI, rebounded to baseline, peaked at 3 days and slowly returned to baseline by 6 months ($p < 0.0001$ by ANOVA). The temporal trends to maximal peak in biomarkers were as follows: immediately post PCI: OxPL-apoB and lipoprotein (a); Day 1- the inflammatory biomarkers IL-6 and CRP; Day 3- coagulation biomarkers OxPL-PLG, plasminogen and tissue plasminogen activity; Day 3-7- plasminogen activator inhibitor; and Day 7-30- complement factor H binding to malondialdehyde-LDL, PAI-1 activity, MDA-LDL IgG and IgM, CuOxLDL IgM, and ApoB-IC IgM and IgG. Most of the biomarkers trended to baseline by 6 months.

Correspondence: Sotirios Tsimikas, Vascular Medicine Program, University of California San Diego, 9500 Gilman Drive, La Jolla CA, 92093-0682, Tel: (858) 534-6109, stsimikas@ucsd.edu..

Disclosures

Dr. Tsimikas is a co-inventor and receives royalties for patents owned by the University of California for the clinical use of oxidation-specific antibodies and currently holds a dual appointment at UCSD and as an employee of Ionis Pharmaceuticals.

Conclusions—PCI results in a specific, temporal sequence of changes in plasma biomarkers. These observations provide insights into the effects of iatrogenic barotrauma and plaque disruption during PCI and suggest avenues of investigation to explain complications of PCI and development of targeted therapies to enhance procedural success.

Keywords

percutaneous coronary intervention; plasminogen; oxidized phospholipids; complement factor H; coagulation and oxidative biomarkers

INTRODUCTION

Percutaneous coronary intervention (PCI) is often associated with release and embolization of plaque contents into the microcirculation.(1),(2) Studies have documented that vascular injury induced by PCI is associated with pro-inflammatory responses that affect immediate and long-term outcomes.(3) Inflammation plays an important role in the pathogenesis of atherosclerosis, and arterial injury caused by PCI results in further downstream release of several inflammatory components.(4),(5) A variety of pro-inflammatory oxidation-specific epitopes (OSEs) are generated during the evolution of early atherosclerotic lesions that transition to ruptured plaques in patients with sudden death.(2),(5),(6) Furthermore, oxidized phospholipids (OxPLs) are released from symptomatic, stenotic lesions in patients undergoing PCI or carotid and peripheral interventions, as detected by mass spectroscopy of captured material in distal protection devices.(7),(8),(9) Finally, plasma biomarkers of oxidized lipids, as measured by circulating levels of OxPL on apoB-100 particles (OxPL-apoB), are significant predictors of the presence and extent of carotid and femoral atherosclerosis, development of new lesions, and increased risk of cardiovascular events, including myocardial infarction, stroke and peripheral arterial disease.(10)

We recently showed that OxPLs are present on plasminogen (OxPL-PLG), which shares high homology with apolipoprotein (a) [apo(a)]. Lipoprotein (a) [Lp(a)] is composed of apo(a) covalently bound to apolipoprotein B-100. In addition to OxPL on Lp(a), OxPL on plasminogen represent a distinct second pool of plasma circulating OxPL and have different pathophysiological consequences.(11) For example, plasminogen enriched with OxPL is associated with enhanced fibrinolysis compared to plasminogen lacking OxPL. This would correlate with less propensity to develop thrombosis, as opposed to the pro-thrombotic and pro-atherogenic properties of Lp(a). Furthermore, OxPL-PLG levels increase following acute myocardial infarction (AMI), suggesting that they are involved in atherothrombosis and may influence outcome after PCI in AMI.

The aim of this study was to assess changes in acute and long-term effect of PCI on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina (SA). We assessed serial changes in OxPL-PLG in patients with SA and evaluated the temporal relationship of a variety of biomarkers measured in the same patients serially prior to and up to 6 months following PCI.

METHODS

Study Population

This is a biomarker substudy of previously described set of studies derived from the same cohort of patients.(7),(9),(12) Venous blood in EDTA was obtained before, immediately after, 6 and 24 hours, 3 and 7 days, and 1, 3, and 6 months after PCI. The current analysis is based on 125 of 159 subjects with available serial plasma samples for measurement of additional biomarkers. Stable patients with successful PCI of a single de novo lesion in a native coronary artery were enrolled in this single-center prospective study. Exclusion criteria included recent (<2 weeks) unstable angina (defined as rest pain with ST-segment changes) or myocardial infarction (MI), bypass graft lesions, total occlusions, and concurrent illnesses (cancer or chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease). Patients with an unsuccessful procedure (residual diameter stenosis >50%) or abrupt occlusion within the first 7 days were excluded from additional analyses. None of the patients had undergone recent (<1 year) interventions of other lesions. PCI was performed according to standard techniques. The study was approved by the hospital research ethics board, and all patients gave informed consent.(12)

A control group of 41 patients undergoing diagnostic angiography with heparin administration and in whom blood was obtained before and immediately after the procedure was also included.

Measurement of Plasminogen, Oxidized Phospholipids on Plasminogen (OxPL-PLG) and Complement Factor H Binding to MDA-LDL

Enzyme linked immunosorbent assay (ELISA) to determine plasminogen and OxPL-PLG plasma levels (**Figure 1**) for each time point was performed as previously described in detail.(11) A serial dilution of purified human plasminogen (Meridian, Saco, ME) was used to generate a standard curve to measure plasminogen levels. The OxPL-PLG assay represents OxPL covalently bound to plasminogen as recognized by murine monoclonal antibody E06 that binds to the PC headgroup of oxidized but not normal phospholipids. In the first description of this assay, data were initially reported in relative light units per 100ms (RLU/100ms). (11) In the current study we now report OxPL-PLG levels as nanomolar (nmol/L or nM) OxPL based on a standard curve of phosphocholine (PC) equivalents, to facilitate comparison of absolute OxPL-PLG levels across studies. The standard curve is generated by plating known concentrations of PC-modified bovine serum albumin (PC-BSA), which has approximately 16 moles of PC/mole of BSA (Biotech Technologies, Novato, California) and is recognized by murine monoclonal antibody E06. Biotin-E06 is then added to detect the number of moles of PC in the linear range of the assay measurements and is measured in RLU. This standard curve is then used to convert the RLU derived from wells containing individual human samples to OxPL equivalents. This new method is reported as nanomoles of PC found on OxPL per liter of plasma (i.e., nanomolar or nM) for each sample. Because each mole of OxPL has 1 PC headgroup recognized by E06, this can be reported as nM PC-OxPL, as previously described for measurement of OxPL on apolipoprotein B-100 (OxPL-apoB).(13),(14), (15),(16) We present the OxPL-PLG data as both RLU and nM PCOxPL to facilitate comparison with prior work.

Complement factor H (CFH) binds the oxidation-specific epitope malondialdehyde, as in modified low-density lipoprotein (MDA-LDL) and is enriched in human vulnerable plaques. (17) As such, it functions as an innate immune protein to protect against MDA-mediated oxidative stress. (18) CFH binding to MDA-LDL (noted as CFH-MDA-LDL) was measured by ELISA as recently described. (17) Microtiter well plates (Thermo scientific, Rochester, NY) were incubated overnight at 4°C with MDA-LDL (50µl at 5µg/ml), produced from purified human low-density lipoprotein (LDL) as described. (7), (17) Wells were washed with PBS, blocked with 1% BSA/TBS at 100 µl/well for 45 minutes at room temperature. After further washing, human plasma (50µL at 1:200 dilution) was added to each well for 75 minutes. After another wash cycle, biotinylated guinea pig anti-human CFH antibody (50µl at 0.25µg/ml) was added for 1 hour. Wells were washed again, and alkaline phosphatase-conjugated NeutrAvidin (Thermo Fisher Scientific Inc., Rockford, IL) diluted at 1:10,000 was added at 50µl/well for 1 hour. After washing with TBS, 50% Lumi-Phos 530 (Lumigen Inc. Southfield, MI) was added at 25µl/well for 75 minutes with light shielding. The plates were read by chemiluminescence detector and reported in RLU/100ms.

Reproducibility of individual plasma levels was verified by analyzing OxPL-apoB and comparing them with values from an earlier measurement, as well as by comparison of plasminogen, OxPL-PLG, and CFH-MDA-LDL plasma levels from samples that underwent repeated thaw-freeze cycles. Coefficient of variability is 4-10%, within-person 5-year reproducibility of frozen samples has been shown to be high ($r=0.78$) and higher than LDL-C and HDL-C; (19), (20) Oxidative biomarker levels are stable over 24 hours on ice (intraclass correlation coefficient 0.96) as well as frozen samples stored under long term conditions, including freeze-thaw cycles. (14), (19), (20), (21)

Coagulation, Oxidation, and Inflammation Biomarkers

For a comprehensive comparison of temporal changes in biomarkers, plasminogen, OxPL-PLG, and CFH-MDA-LDL plasma levels were put in temporal perspective to additional coagulation, oxidation, and inflammation biomarkers that were measured previously from this cohort. (7), (9), (12) Coagulation biomarkers measured consisted of urokinase (uPA) and tissue plasminogen activator (tPA) activity, uPA antigen, and plasminogen activator inhibitor type 1 (PAI-1) activity as previously reported. (9), (12) Indirect markers of oxidation-specific epitopes such as IgG and IgM autoantibodies to MDA-LDL and copper oxidized LDL (CuOxLDL), and peptide mimotopes that reflect the 3-dimensional structure of MDA have been reported. (9), (13), (22), (23) Inflammatory biomarkers included interleukin-6 (IL-6) and high sensitivity C-reactive protein (hsCRP) as previously reported. (2), (23) IgM and IgG immune complexes with apolipoprotein B (apoB-IC IgM and IgG) were not previously published.

Statistical Analyses

For grouped numerical values a mean value $\pm$ standard deviation (mean $\pm$ SD) was calculated. Analysis of quantitative parameters within groups was performed with the Student t-test, and temporal changes among groups with repeated measures one-way ANOVA with the Bonferroni post-test for multiple comparisons. Data presented in the text

and tables are mean $\pm$ SD and in figures the mean value $\pm$ standard error of the mean (mean $\pm$ SEM).

RESULTS

Patient and lesion related characteristics are reported in **Table 1** and represent typical characteristics of patients with stable angina, with the exception of relatively low use of stent placement reflecting the era of patient recruitment.

Temporal changes in Plasminogen and OxPL-PLG

Temporal changes in absolute values of plasminogen and OxPL-PLG are shown in **Table 2**. Mean plasminogen plasma levels at baseline were 20.8 ± 4.6 mg/dl and changed significantly (ANOVA, $p<0.0001$) following PCI. When expressed as mean percent change from baseline, plasminogen values decreased $-10.6\pm 16.2\%$ ($p<0.0001$) immediately post-PCI, increased $9.7\pm 25.4\%$ ($p<0.0001$) at 3 days and returned to baseline values ($1.3\pm 22.3\%$, $p=0.528$) at 6 months (**Figure 2**).

Mean OxPL-PLG plasma levels at baseline were 229 ± 93 nM PC-OxPL and changed significantly (ANOVA, $p<0.0001$) post-PCI. OxPL-PLG changes from baseline were overall similar to the changes of plasminogen, but the extent was more pronounced ($\sim 1.8\times$). A reduction of $-14.9\pm 34.2\%$ ($p<0.0001$) in OxPL-PLG was noted post-PCI with an increase of $19.6\pm 54.7\%$ ($p<0.0001$) at 3 days with return to baseline ($4.0\pm 35.8\%$, $p=0.210$) by 6 months. Changes in absolute values and as percent change from baseline are shown in **Figure 2**.

Complement Factor H Binding to MDA-LDL

Absolute plasma levels of CFH-MDA-LDL decreased significantly during PCI ($p=0.0003$), rose back to baseline levels after 6 hours, and remained at this level over the follow-up period. The percent change from baseline CFH-MDA-LDL decreased during PCI (-11.5 ± 16.7 , $p<0.0001$), but then increased significantly after the procedure to a maximum at 3 days ($6.1\pm 23.2\%$, $p=0.003$) and remained elevated up to 6 months after the procedure ($4.6\pm 21.0\%$, $p=0.011$) (**Table 2** and **Figure 3**).

A second analysis evaluating only subjects with a full complement of blood samples at all 9 timepoints did not show any significant differences in changes in plasminogen, OxPL-PLG or CFH-MDA-LDL (data not shown).

Subgroup Analysis According to Baseline Characteristics

Subgroup analyses for gender differences, diabetic patients, previous MI, and restenosis are presented in **Figure 4**. OxPL-PLG levels were significantly lower in patients with male gender, diabetes, prior MI and with subsequent restenosis. Plasminogen levels were significantly lower in patients with male gender, diabetes, and prior MI but not with subsequent restenosis. CFHMDA-LDL levels were not different among subgroups.

Biomarker levels according to other variables such as lesion characteristics and cardiovascular risk factors are provided in a **Supplementary Figure**. Plasminogen levels

were significantly lower in patients without ulcerated plaques, no involvement of the left circumflex artery, no history of smoking, and patients receiving stents. OxPL-PLG levels were significantly lower in patients with hypertension and in patients receiving stents. CFH-MDA-LDL levels were significantly lower in patients with concentric lesions, without involvement of the left circumflex, and in patients receiving stents.

No significant changes pre and post angiography were noted in the control group in any of the above variables (data not shown).

Temporal Changes in Oxidative, Inflammatory and Coagulation Biomarkers following Percutaneous Coronary Intervention

Figure 5 shows time-dependent changes expressed as percent change from baseline of all biomarkers that were assessed in this cohort. The dashed green line represents the peak levels at the specific timepoints in the graph. The p-values indicate significant changes in the trend assessed by ANOVA. The earliest biomarker changes were noted in OxPL-apoB and Lp(a) which peaked immediately following PCI, representing approximately 30 minutes to 2 hours of blood sampling from sheath placement prior to PCI. IL-6 levels peaked at 24h and C-reactive protein (CRP), which is upregulated by IL-1 signaling, peaked at 3 days post PCI. OxPL-PLG and the coagulation factors plasminogen, uPA activity and PAI-1 activity, as well as CFH-MDA-LDL, MDA-LDL IgG and IgM, and CuOxLDL IgM decreased immediately following PCI and then increased above baseline to a maximum at 3 days to one month after the procedure. CFH-MDA-LDL, PAI-1 activity, and MDA-LDL IgG peaked between 7 days. MDA-LDL IgM, CuOxLDL IgM, ApoB-IC IgM and IgG peaked at 1 month. uPA antigen and activity peaked at 3 months, and CuOxLDL IgG and peptide mimotopes to MDA-LDL at 6 months post PCI.

DISCUSSION

The present study demonstrates that uncomplicated PCI results in acute decreases in plasminogen and OxPL carried by plasminogen, followed by rebound increase by 24 hours. Furthermore, distinct temporal changes were noted in a variety of biomarkers. Oxidative biomarkers and Lp(a), which is a carrier of OxPL, rise first and likely emanate from the treated site as previously shown in material captured from distal protection devices.(2),(5), (6) These biomarkers are followed by changes in inflammatory biomarkers, coagulation factors and finally by indirect measures of oxidized lipoproteins. These observations provide insights into biomarkers reflecting iatrogenic plaque disruption putatively occurring during PCI and suggest analogous avenues of investigation to address temporal pathophysiological relationships of spontaneous plaque disruption.

In an earlier study in the same group of patients and in a second study of acute coronary syndromes,(24) we showed acute increases in circulating OxPL-apoB, which primarily reflects OxPL on Lp(a).(7) We hypothesized that OxPLs, which are preferentially bound to Lp(a), become released from disrupted atherosclerotic lesions. We have recently documented the strong presence of OxPL in progressing and ruptured human atherosclerotic lesions.(5) Furthermore, we have shown that percutaneous coronary, carotid, renal and peripheral arterial interventions result in downstream release of OxPL and oxidized

cholesteryl esters.(2) Such vasoactive compounds, along with others such as endothelin-1 and other vasoactive compounds in plaque debris,(25),(26),(27),(28) have the ability to promote downstream vasoconstriction and atherothrombosis resulting in no-reflow phenomenon, may compromise procedural success, and complicate clinical outcome.(29)

We now extend these observations to the other major carrier of OxPL in plasma, plasminogen. As opposed to OxPL on Lp(a) which are associated with atherothrombosis and increased risk of CVD events, the presence of OxPL on plasminogen potentiates fibrinolysis, which would be a potential benefit during and following PCI.(11) Interestingly, in contrast to increases in OxPL-apoB and Lp(a), plasminogen and OxPL-PLG showed acute decreases post PCI with subsequent rebound above baseline levels. Although this type of clinical study cannot define the mechanisms behind these observations, it does suggest the hypothesis that there may be consumption of plasminogen and its associated phospholipids during PCI that may tip the balance to increased predisposition to clotting by generating a transient pro-thrombotic state. In settings where the balance of pro- and anti-thrombotic pathways is critical, such as in acute coronary syndromes or in lesions with high-risk characteristics, such as those that have ruptured or have visible thrombus, these changes may be associated with higher risk for peri-procedural events. Similar decreases of plasminogen levels have been reported during septic shock, which also may have pro-thrombotic properties.(30) Consistent with these findings, subgroups traditionally noted by higher risk, such as males, patients with prior MI or diabetes, had lower level of OxPL-PLG post PCI.

CFH is the major inhibitor of the alternative pathway of complement activation, binds to MDA of OSEs,(17) and plays a role in age-related macular degeneration (AMD).(31) Association of the single nucleotide polymorphism (SNP) Y402H of the CFH gene with increased cardiovascular risk has been controversial.(32),(33),(34),(35) However, complement activation has been shown to be higher in individuals presenting with ACS,(36) and recently to be associated with an anti-coagulant role.(37) The biological activity of CFH binding to MDA-LDL decreased by ~12% post PCI, and there was an increase of ~6% at 3-7 days post PCI that remained until 6 months. Although the reason cannot be determined from this study, MDA-binding capacity as reflected by CFH binding, may also play a role in the peri-procedural period.

The array of 18 oxidative, inflammatory, and coagulation biomarkers provides new insights into temporal changes of individual constituents before, during, and after atherosclerotic plaque disruption. Based on these observations, one can conclude that material known to be directly present in lesions, such as OxPL and Lp(a) rise first and are accompanied temporally by acute reduction in OxPL-PLG, then followed by a generalized inflammatory state, and finally by increases in coagulation factors. IL-6 is known to upregulate CRP and plasminogen, and this may explain these later increases.(38) The late rise in indirect measures of markers of OxLDL may reflect the acute plaque disruption and activation of the adaptive immune system in dealing with these released oxidative neoepitopes in the circulation or exposed neoepitopes in the atherosclerotic plaque. These observations provide a fairly comprehensive and unique assessment into changes in a variety of biomarkers

reflecting iatrogenic plaque rupture and may be useful in further studies of spontaneous plaque rupture.

Although our group and others have studied individual biomarkers, or even panels of related biomarkers, this study is unique in not only measuring such a comprehensive list of serially measured biomarkers over 6 months. The unique study design allowed an assessment of several distinct pathophysiological pathways to be evaluated simultaneously and assessment of their temporal relationship to PCI.

LIMITATIONS

Although this study shows temporal changes in a variety of biomarkers, basic investigations are needed to provide mechanistic insights and outcomes studies are needed to define the clinical implications into these observations. Due to the fact this was an investigator-initiated study without significant study support, and the that patients were derived from a wide geographic area, and that the local caregivers were responsible for procuring blood samples and sending them to the central site, all timepoints could not be obtained in all patients, which may have influenced study findings. However, we saw no significant differences in patients with a full set of samples versus those without. The rate of stent placement was relatively low by current standards, reflecting the era when these patients were recruited. However, we did not find differences in patients undergoing balloon angioplasty vs. stent placement, although this analysis may have been underpowered. Finally, statin therapy was not recorded in the database and we cannot assess its effect on these biomarkers.

CLINICAL IMPLICATIONS

The temporal changes in the oxidative, coagulation and inflammatory biomarkers may have clinical implications now and in the future. For example, in a recent study,(39) we showed mean baseline levels of plasminogen and OxPL-PLG were lower in acute MI than in the stable CAD, consistent with prior data.(11) However, mean baseline levels of plasminogen and OxPLPLG were also lower in atherothrombotic versus non-atherothrombotic MI. These findings may reflect a reduced fibrinolytic capacity associated with an increased risk of atherothrombotic events, and allow differentiation and clinical evaluation of stable CAD from unstable CAD and atherothrombotic MI. In addition, these findings may allow “biotheranostic” applications (i.e. biomarker, therapeutics and diagnostic imaging) in future studies.(40) In the example if OxPL on lipoproteins is the biotheranostic target, it can be measured in the plasma as a biomarker to screen for high risk or diagnose a higher risk patient.(2),(41),(42) If the plasma level is elevated, one can employ nuclear or magnetic resonance imaging to localize the source.(43) Finally one may utilize passive immunization in the form of a therapeutic dose of antibody to treat the source, as has been shown with antibodies E06(44) and IK17 in experimental models.(45),(46)

CONCLUSION

PCI results in a unique expression and temporal sequence of oxidative, inflammatory and coagulation and immunity related biomarkers that may have clinical implications in plaque disruption and plaque vulnerability.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding Sources

This study was funded by the Swiss National Science Foundation PBBSP3-124742 and the Swiss Academy of Medical Sciences PASMP3_132566 (G.L.) and NIH HL119828, HL055798, HL088093, HL106579, HL078610, HL124174. (S.T.).

References

1. Prati F, Pawlowski T, Gil R, Labellarte A, Gziut A, Caradonna E, et al. Stenting of culprit lesions in unstable angina leads to a marked reduction in plaque burden: a major role of plaque embolization? A serial intravascular ultrasound study. *Circulation*. May 13; 2003 107(18):2320–5. [PubMed: 12707236]
2. Ravandi A, Leibundgut G, Hung M-Y, Patel M, Hutchins PM, Murphy RC, et al. Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. *J Am Coll Cardiol*. Feb 21.2014 63:1961–71. [PubMed: 24613321]
3. Juni RP, Duckers HJ, Vanhoutte PM, Virmani R, Moens AL. Oxidative stress and pathological changes after coronary artery interventions. *J Am Coll Cardiol*. Apr 9; 2013 61(14):1471–81. [PubMed: 23500310]
4. Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S, et al. Activation of nuclear factor- κ B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. *Circulation*. Feb 5; 2002 105(5):633–8. [PubMed: 11827931]
5. van Dijk RA, Kolodgie F, Ravandi A, Leibundgut G, Hu PP, Prasad A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. *J Lipid Res*. Dec; 2012 53(12):2773–90. [PubMed: 22969153]
6. Choi S-H, Yin H, Ravandi A, Armando A, Dumlao D, Kim J, et al. Polyoxygenated cholesterol ester hydroperoxide activates TLR4 and SYK dependent signaling in macrophages. *PLoS ONE*. 2013; 8(12):e83145. [PubMed: 24376657]
7. Tsimikas S, Lau HK, Han K-R, Shortal B, Miller ER, Segev A, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. *Circulation*. Jun 29; 2004 109(25):3164–70. [PubMed: 15184281]
8. Fefer P, Tsimikas S, Segev A, Sparkes J, Otsuna F, Kolodgie F, et al. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. *Cardiovasc Revasc Med*. Jan; 2012 13(1):11–9. [PubMed: 22079685]
9. Segev A, Strauss BH, Witztum JL, Lau HK, Tsimikas S. Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. *Am Heart J*. Nov; 2005 150(5):1007–14. [PubMed: 16290986]
10. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic

cardiovascular disease: five-year prospective results from the Bruneck study. *J Am Coll Cardiol*. Jun 6; 2006 47(11):2219–28. [PubMed: 16750687]

11. Leibundgut, G.; Arai, K.; Orsoni, A.; Yin, H.; Scipione, C.; Miller, ER., et al. *J Am Coll Cardiol*. Vol. 59. Elsevier Inc; Apr 17. 2012 Oxidized Phospholipids Are Present on Plasminogen, Affect Fibrinolysis, and Increase Following Acute Myocardial Infarction.; p. 1426–37.
12. Strauss BH, Lau HK, Bowman KA, Sparkes J, Chisholm RJ, Garvey MB, et al. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. *Circulation*. Oct 12; 1999 100(15):1616–22. [PubMed: 10517732]
13. Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. *Biomark Med*. Oct; 2011 5(5):673–94. [PubMed: 22003918]
14. Bertoia ML, Pai JK, Lee J-H, Taleb A, Joosten MM, Mittleman MA, et al. Oxidation-specific biomarkers and risk of peripheral artery disease. *J Am Coll Cardiol*. May 28; 2013 61(21):2169–79. [PubMed: 23541965]
15. Capoulade R, Chan KL, Yeang C, Mathieu P, Bossé Y, Dumesnil JG, et al. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. *J Am Coll Cardiol*. Sep 15; 2015 66(11):1236–46. [PubMed: 26361154]
16. Byun YS, Lee J-H, Arsenault BJ, Yang X, Bao W, DeMicco D, et al. Relationship of Oxidized Phospholipids on Apolipoprotein B-100 to Cardiovascular Outcomes in Patients Treated With Intensive Versus Moderate Atorvastatin Therapy: The TNT Trial. *J Am Coll Cardiol*. Apr 7; 2015 65(13):1286–95. [PubMed: 25835440]
17. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HPN, Charbel Issa P, et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. *Nature*. Oct 6; 2011 478(7367):76–81. [PubMed: 21979047]
18. Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. *Annu Rev Pathol*. 2014; 9:73–102. [PubMed: 23937439]
19. Tsimikas S, Mallat Z, Talmud PJ, Kastelein JJP, Wareham NJ, Sandhu MS, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. *J Am Coll Cardiol*. Sep 14; 2010 56(12):946–55. [PubMed: 20828647]
20. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. *Arterioscler Thromb Vasc Biol*. Aug; 2007 27(8):1788–95. [PubMed: 17541022]
21. Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. *J Am Coll Cardiol*. May 2; 2006 47(9):1803–10. [PubMed: 16682304]
22. Amir S, Hartvigsen K, Gonen A, Leibundgut G, Que X, Jensen-Jarolim E, et al. Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. *J Lipid Res*. Jul; 2012 53(7):1316–26. [PubMed: 22508944]
23. Segev A, Kassam S, Buller CE, Lau HK, Sparkes JD, Connelly PW, et al. Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. *Eur Heart J*. Jun; 2004 25(12):1029–35. [PubMed: 15191773]
24. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. *J Am Coll Cardiol*. Feb 5; 2003 41(3):360–70. [PubMed: 12575961]
25. Heusch G, Kleinbongard P, Böse D, Levkau B, Haude M, Schulz R, et al. Coronary microembolization: from bedside to bench and back to bedside. *Circulation*. Nov 3; 2009 120(18):1822–36. [PubMed: 19884481]
26. Sato H, Iida H, Tanaka A, Tanaka H, Shimodouzo S, Uchida E, et al. The decrease of plaque volume during percutaneous coronary intervention has a negative impact on coronary flow in acute myocardial infarction: a major role of percutaneous coronary intervention-induced embolization. *J Am Coll Cardiol*. Jul 21; 2004 44(2):300–4. [PubMed: 15261922]

27. Leineweber K, Böse D, Vogelsang M, Haude M, Erbel R, Heusch G. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. *J Am Coll Cardiol.* Mar 7; 2006 47(5):981–6. [PubMed: 16516081]
28. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, et al. Release of endothelin 1 and angiotensin II induced by percutaneous transluminal coronary angioplasty. *Catheter Cardiovasc Interv.* Sep; 2000 51(1):42–9. [PubMed: 10973017]
29. Schachinger V, Halle M, Minners J, Berg A, Zeiher AM. Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. *J Am Coll Cardiol.* Oct 1; 1997 30(4):927–34. [PubMed: 9316520]
30. Gallimore MJ, Aasen AO, Erichsen NS, Larsbraaten M, Lyngaas K, Amundsen E. Plasminogen concentrations and functional activities and concentrations of plasmin inhibitors in plasma samples from normal subjects and patients with septic shock. *Thromb Res.* Jun 1; 1980 18(5):601–8. [PubMed: 6158114]
31. Donoso LA, Vrabec T, Kuivaniemi H. The role of complement Factor H in age-related macular degeneration: a review. *Surv Ophthalmol.* May; 2010 55(3):227–46. [PubMed: 20385334]
32. Koeijvoets KCMC, Mooijaart SP.; Dallinga-Thie GM, Defesche JC.; Steyerberg EW, Westendorp RGJ., et al. Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia. *Eur Heart J.* Mar; 2009 30(5):618–23. [PubMed: 19098018]
33. Sofat, R.; Casas, JP.; Kumari, M.; Talmud, PJ.; Ireland, H.; Kivimaki, M., et al. Atherosclerosis. Vol. 213. Elsevier; Nov. 2010 Genetic variation in complement factor H and risk of coronary heart disease: Eight new studies and a meta- analysis of around 48,000 individuals.; p. 184-90.
34. Pai JK, Manson JE, Rexrode KM, Albert CM, Hunter DJ, Rimm EB. Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women. *Eur Heart J.* Jun; 2007 28(11):1297–303. [PubMed: 17483111]
35. Meng W, Hughes A, Patterson CC, Belton C, Kamaruddin MS, Horan PG, et al. Genetic variants of complement factor H gene are not associated with premature coronary heart disease: a family-based study in the Irish population. *BMC Med Genet.* 2007; 8:62. [PubMed: 17877809]
36. Iltumur K, Karabulut A, Toprak G, Toprak N. Complement activation in acute coronary syndromes. *APMIS.* Mar; 2005 113(3):167–74. [PubMed: 15799759]
37. Ferluga J, Kishore U, Sim RB. A potential anti-coagulant role of complement factor H. *Molecular Immunology.* Jun; 2014 59(2):188–93. [PubMed: 24632373]
38. Ramharack R, Barkalow D, Spahr MA. Dominant negative effect of TGF-beta1 and TNF- alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. *Arterioscler Thromb Vasc Biol.* Jun; 1998 18(6):984–90. [PubMed: 9633941]
39. DeFilippis AP, Chernyavskiy I, Amraotkar AR, Trainor PJ, Kothari S, Ismail I, et al. Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction. *J Thromb Thrombolysis.* Oct 28,2015
40. Leibundgut, G.; Witztum, JL.; Tsimikas, S. Current Opinion in Pharmacology. Elsevier Ltd; Mar 28. 2013 Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis.; p. 1-12.
41. Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, et al. Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events. *J Am Coll Cardiol.* Nov 20; 2012 60(21):2218–29. [PubMed: 23122790]
42. Tsimikas S, Duff GW, Berger PB, Rogus J, Huttner K, Clopton P, et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). *J Am Coll Cardiol.* May 6; 2014 63(17): 1724–34. [PubMed: 24530664]
43. Briley-Saebo K, Yeang C, Witztum JL, Tsimikas S. Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions. *J Cardiovasc Transl Res.* Nov; 2014 7(8):719–36. [PubMed: 25297940]
44. Binder CJ, Horkko S, Dewan A, Chang M-K, Kieu EP, Goodyear CS, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between *Streptococcus pneumoniae* and oxidized LDL. *Nat Med.* Jun; 2003 9(6):736–43. [PubMed: 12740573]

45. Tsimikas S, Miyanohara A, Hartvigsen K, Merki E, Shaw PX, Chou M-Y, et al. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. *J Am Coll Cardiol.* Oct 11; 2011 58(16):1715–27. [PubMed: 21982317]
46. Fang L, Green SR, Baek JS, Lee S-H, Ellett F, Deer E, et al. In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. *J Clin Invest.* Dec; 2011 121(12):4861–9. [PubMed: 22105168]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1. Plasminogen and OxPL-PLG Chemiluminescence Assays

The figure displays the methodology of the plasminogen and OxPL-PLG chemiluminescence assays. ms: mouse, Mab: monoclonal antibody, PC: phosphocholine, OxPL: oxidized phospholipid, GPahuPLG: polyclonal guinea pig anti-human plasminogen IgG-antibody, EO6: IgM-Mab, asterisk indicates the biotin-Neutravidin-alkaline phosphatase complex. Chemiluminescence was measured in relative light units (RLU) at 440nm for 100ms.

Figure 2. Plasma Levels of Plasminogen and OxPL-PLG post PCI

OxPL-PLG and plasminogen (A,B) expressed in relative light units per 100ms (RLU), nM PC of OxPL-PLG and mg/dl of plasminogen (C,D), and mean percent change from baseline values (E,F). The curves were analyzed by ANOVA. Significant differences were found between pre-post, pre-3d, pre-1w, and pre-1m values for plasminogen; and between pre-post, pre-24h, pre-3d, pre-1w, and pre-1m values for OxPL-PLG by Student's t-test. Absolute values are given in Table 1. h: hours, d: days, w: week, m: month(s).

Figure 3. CFH-MDA-LDL Plasma Levels post PCI

CFH-MDA-LDL levels (**A**) expressed as RLU/100ms and (**B**) as mean percent change from baseline values. The curves were analyzed by ANOVA. Significant differences were found between pre-post values for absolute CFH-MDA-LDL levels; and between pre-post, pre-24h, pre-3d, pre-1w, pre-1m, pre-3m, and pre-6m values for CFH-MDA-LDL changes from baseline by Student's t-test. Absolute values are given in Table 1. h: hours, d: days, w: week, m: month(s).

Figure 4. Subgroup Analyses of Changes in OxPL-PLG, Plasminogen and CFH-MDA-LDL
Relationship of changes in OxPL-PLG, plasminogen, and CFH-MDA-LDL plasma levels in RLU/100ms to subgroups of gender, diabetes, previous MI and restenosis in patients undergoing PCI. Significant differences between genders were found at 1w and 1m for OxPL-PLG levels and at pre, post, 6h, 1w, 1m, and 3m for plasminogen levels; in diabetic patients at pre for OxPL-PLG levels and at pre and 6m for plasminogen levels; in patients with prior MI at pre and post for plasminogen levels; in patients with subsequent restenosis

at 1w and 1m for OxPL-PLG levels by Student's t-test. h: hours, d: days, w: week, m: month(s).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 5. Time Dependence of Oxidative, Inflammatory and Coagulation Biomarkers Following PCI

Panels A to R show time related changes in mean percent change from baseline values in oxidative, inflammatory and coagulation biomarkers following PCI. Friedman's 2-way analysis of variance by Ranks was used to determine significant changes. $P < 0.05$ was considered statistically significant. The dashed green line indicates time dependence of the highest peak of the plasma values. Original data: Panel A, B, M, N, O, and P (8); C and D (19); K (18); G, H, J, L (13). h: hours, d: days, w: week, m: month(s).

Table 1**Patient and Lesion Characteristics**

Characteristics	N=125 (%)
Age, years	56.3±9.9
Gender, female	27 (21.6)
CCS Class	
CCS 1	12 (9.6)
CCS 2	59 (47.2)
CCS 3	51 (40.8)
CCS 4	3 (2.4)
Cardiovascular risk factors	
Diabetes mellitus	26 (20.8)
Hypertension	60 (48.0)
Smoking	51 (40.8)
Previous MI	35 (28.0)
Medication	
Heparin	33 (34.4)
Nitroglycerine	71 (79.8)
Beta-blockers	90 (72.0)
Ca-Channel blockers	71 (56.8)
Vessel undergoing PCI	
Left anterior descending artery	72 (57.6)
Left circumflex artery	25 (20.0)
Right coronary artery	28 (22.4)
AHA/ACC Lesion type	
A	43 (34.4)
B1	49 (39.2)
B2	26 (20.8)
C	7 (5.6)
Lesion appearance	
Eccentric	39 (31.2)
Ulceration	10 (8.0)
Vessel wall irregular	23 (18.4)
Lesion length, mm	
Pre PCI	9.21±3.13
Post PCI	7.62±3.13
At 6 months	9.36±4.10
Vessel diameter, mm	
Pre PCI	2.79±0.54
Post PCI	2.94±0.55
At 6 months	2.93±0.57
Lesion diameter, mm	

Characteristics	N=125 (%)
Pre PCI	0.86±0.32
Post PCI	2.13±0.67
At 6 months	1.72±0.74
Diameter stenosis, %	
Pre PCI	69.10±10.13
Post PCI	28.45±12.73
At 6 months	41.67±21.04
Procedure, Stent	39 (31.2)
Restenosis at 6 months	42 (33.6)

Table 2
Baseline and Follow-up Plasma Levels of Plasminogen, OxPL-PLG, and CFH-MDA-LDL

	Pre	Post	6h	24h	3d	1w	1m	3m	6m	P-value
Plasminogen, RLU										
Mean±SD	47,790±8,707	41,957±7,753	45,849±9,193	48,464±10,158	51,263±9,345	50,784±8,261	48,971±8,570	46,875±9,513	47,218±9,385	<0.0001
Plasminogen, mg/dl										
Mean±SD	20.8±4.6	17.7±4.1	19.6±5.3	21.0±5.9	22.7±5.0	22.4±4.4	21.4±4.6	20.3±5.1	20.5±5.0	<0.0001
OxPL-PLG, RLU										
Mean±SD	23,203±7,932	19,046±7,936	23,134±9,897	23,754±9,234	25,124±7,913	24,969±8,478	24,347±7,960	23,216±8,434	22,327±8,308	<0.0001
OxPL-PLG, nM PC										
Mean±SD	229±93	180±93	228±116	235±109	252±93	250±100	242±94	229±99	219±98	<0.0001
CFH-MDA-LDL, RLU										
Mean±SD	31,369±9,722	27,193±8,590	30,701±10,656	32,222±10,828	32,426±10,851	32,105±10,359	31,513±10,603	31,738±10,714	31,464±10,009	<0.0001

P-value indicates significance level of ANOVA test.